TIMM17A is an essential component of the TIM23 complex, a mitochondrial inner membrane translocase that mediates the import of transit peptide-containing proteins across the mitochondrial inner membrane into the matrix 1. As one of two human orthologs of yeast Tim17, TIMM17A forms highly conserved core TIM23 variants with TIMM23 and ROMO1, with structural and mechanistic features preserved across species 1. TIMM17A stability is tightly regulated by mitochondrial quality control mechanisms: unoccupied TIM23 complexes expose a C-terminal degron on TIMM17A for ATP-dependent degradation by the protease YME1L1 2, while the prohibitin complex and OCIAD1 stabilize the TIMM17A-containing translocase variant to protect it from YME1L1-mediated degradation 3. Clinically, TIMM17A dysregulation is associated with multiple pathologies. Downregulation of TIMM17A occurs in heart failure from both ischemic and dilated cardiomyopathy, contributing to mitochondrial quality control defects 4. Conversely, elevated TIMM17A expression represents an adverse prognostic marker in breast cancer and lung adenocarcinoma, associating with higher tumor grade, nodal involvement, metastasis potential, and reduced overall survival 567. MicroRNA-593-3p suppresses breast cancer growth and metastasis by targeting TIMM17A 8, suggesting therapeutic potential for modulating TIMM17A expression in cancer treatment.